A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy-Reference-Cited by-同舟云学术

A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy

Published:2019-11 Issue:2 Volume:155 Page:270-274
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Gronwald Jacek,Lubinski Jan,Huzarski Tomasz,Cybulski Cezary,Menkiszak Janusz^ORCID,Siołek Monika,Stawicka Małgorzata,Sun Ping,Kim Shana J.,Kotsopoulos Joanne^ORCID,Narod Steven A.^ORCID

Funder

Canada Research Chair

Canadian Cancer Society Research Institute

Peter Gilgan Foundation Tour de Bleu

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference7 articles.

1. Hereditary ovarian cancer clinical study group. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation;Kotsopoulos;Gynecol. Oncol.,2018

2. Hereditary ovarian cancer clinical study group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation;Finch;JAMA,2006

3. Hereditary ovarian cancer in Poland;Menkiszak;Int. J. Cancer,2003

4. United Kingdom familial ovarian cancer screening study collaborators. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study;Rosenthal;J. Clin. Oncol.,2017

5. Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk - combined results from two screening trials;Skates;Clin. Cancer Res.,2017

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations;JAMA Oncology;2024-04-01

2. Reply to the Letter to the Editor ‘There is no place for ovarian cancer screening in hereditary breast–ovarian cancer syndromes (in regard to “ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes”)’ by W. Tjalma;Annals of Oncology;2024-01

3. There is no place for ovarian cancer screening in hereditary breast–ovarian cancer syndromes;Annals of Oncology;2024-01

4. Choices for cancer prevention for women with a BRCA1 mutation? a personal view;Hereditary Cancer in Clinical Practice;2023-11-29

5. Menopausal hormone therapy for BRCA mutation carriers: A case for precision medicine;Maturitas;2023-11